Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bone graft & orthobiologics cases in Missouri: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 12% on average (190 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 30 | 1,081 | 40% |
| 2020 | 23 | 806 | 43% |
| 2021 | 23 | 719 | 48% |
| 2022 | 15 | 578 | 51% |
| 2023 | 8 | 419 | 55% |
| 2024 | 9 | 352 | 57% |
| 2025 from claims | – | 320 259–376 | 58% |
| 2026 forecast | – | 322 252–405 | 58% |
| 2027 forecast | – | 323 240–427 | 59% |
| 2028 forecast | – | 324 230–448 | 60% |
| 2029 forecast | – | 325 221–467 | 60% |
| 2030 forecast | – | 326 214–484 | 61% |
Graft add-on codes identify surgeons using biologics across spine and extremity cases. Professional codes (what the surgeon bills): CPT 20930, 20931, 20936, 20937, 20938, 20939.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Missouri; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 73% inpatient hospital, 25% hospital outpatient, 1% surgery center, 1% office.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Michigan | 27 | 796−14%/yr | −14%/yr | 0.9 | 3% | 740 in 2030−1.1%/yr |
| Illinois | 16 | 682−8.3%/yr | −8.3%/yr | 0.5 | 1% | 720 in 2030+0.9%/yr |
| Ohio | 17 | 623−12%/yr | −12%/yr | 0.5 | 1% | 580 in 2030−1%/yr |
| Indiana | 13 | 404−19%/yr | −19%/yr | 0.6 | 0% | 330 in 2030−3.2%/yr |
| Minnesota | 6 | 371−9%/yr | −9%/yr | 0.8 | 0% | 410 in 2030+1.7%/yr |
| Iowa | 8 | 349+3.2%/yr | +3.2%/yr | 0.8 | 0% | 470 in 2030+5.1%/yr |
| Nebraska | 6 | 320−12%/yr | −12%/yr | 1.2 | 3% | 320 in 2030+0.2%/yr |
| Wisconsin | 4 | 304−9.5%/yr | −9.5%/yr | 0.5 | 1% | 360 in 2030+2.7%/yr |
| Kansas | 6 | 241−8.6%/yr | −8.6%/yr | 0.6 | 0% | 210 in 2030−2.4%/yr |
| South Dakota | 5 | 198−11%/yr | −11%/yr | 1.5 | 0% | 210 in 2030+1.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 245 | 52,294−2.9%/yr | −2.9%/yr | 80.21.0× | 23% | 55,400 in 2030+1%/yr |
| Skin substitutes & wound grafts | 32 | 8,053+4.4%/yr | +4.4%/yr | 7.71.0× | 47% | 8,660 in 2030+1.2%/yr |
Bone graft & orthobiologics in every state, and its device makers · Every procedure market in Missouri · Every state · Compare with Michigan
Kuros Biosciences leads with 35% of company spending on these surgeons in 2025, +13 pts on 2024.
In 2025, 15 companies reported engagement with Missouri’s surgeons worth $124K in consulting, speaking, meals and travel tied to these products, about $14K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.